Keywords
How to Cite
Abstract
Objectives: To report a case of response to ustekinumab in a patient with severe psoriasis when adalimumab dose escalation fail.
Case Description: A 35-year-old Caucasian male was diagnosed as having psoriasis. He was started on methotrexate followed cyclosporine. Despite these treatments, the patient experienced an abrupt deterioration of his psoriasis [PASI 35]. The patient started treatment with adalimumab: initial dose of 80mg followed by 40mg in week 2. At week 3 he continued on adalimumab 40mg/two weeks with significant reduction of psoriasis. After 8 months of adalimumab therapy, he referred that adalimumab was effective only during the first week of treatment. The patient gave his written informed consent for adalimumab dose intensification. He started adalimumab 40mg/week, with an improvement of psoriasis. After 7 months of adalimumab dose intensification, the psoriasis worsened [PASI score =25 and CDLQI score 20]. We discontinued adalimumab and started therapy with ustekinumab, 45mg subcutaneously, was administered at weeks 0, 4 and every 12 weeks. The clinical response was impressive; at week 12 a PASI 90 response was achieved while the CDLQI score fell to the scale of 7. Efficacy was maintained after a 12 months of ustekinumab therapy.
Conclusions: This case report provides valuable insight into the efficacy and tolerability of ustekinumab in a patient with severe psoriasis when adalimumab dose escalation fails. To our knowledge this is the first case published to date that describes the clinical efficacy of ustekinumab when adalimumab intensification dose escalation fails.
References
Schön MP, Boehncke WH. Psoriasis. N Engl J Med 2005; 352: 1899-12. http://dx.doi.org/10.1056/NEJMra041320
Papp KA, Dekoven J, Parsons L, Pirzada S, Robern M, Robertson L, Tan JK. Biologic therapy in psoriasis: perspectives on associated risks and patient management. J Cutan Med Surg 2012; 16153-168.
Famenini S, Wu JJ. The efficacy of ustekinumab in psoriasis. J Drugs Dermatol 2013; 12: 317-20.
Downs AM. Observational case series on a group of patients with severe psoriasis who failed to respond to antitumour necrosis factor a biologics and switched to ustekinumab. Br J Dermatol 2010; 63; 443-44.
Vena GA, Galluccio A, De Simone C, Mastrandrea V, Buquicchio R, La Greca S, et al. A multicenter open-label experience on the response of psoriasis to Adalimumab and effect of dose escalation in non-responders: the Aphrodite project. Int J Immunopatholn Pharmacol 2009; 22: 227-33.
Patel R, Cafardi JM, Patel N, Sami N, Cafardi JA. Tumor necrosis factor biologics beyond psoriasis in dermatology. Expert Opin Biol Ther 2011; 10: 1341-59. http://dx.doi.org/10.1517/14712598.2011.590798
Schmitt J, Zhang Z, Wozel G, Meurer M, Kirch W. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderatetosevere psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 2008; 159: 513-26. http://dx.doi.org/10.1111/j.1365-2133.2008.08732.x
Hsu S, Papp KA, Lebwohl MG, Bagel J, Blauvelt A, et al. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol 2012; 148: 95-102. http://dx.doi.org/10.1001/archdermatol.2011.1410
Khalid JM, Fox KM, Globe G, Maguire A, Chau D. Treatment patterns and therapy effectiveness in psoriasis patients initiating biologic therapy in England. J Dermatolog Treat 2013.
Leonardi C, Sobell JM, Crowley JJ, Mrowietz U, Bao Y, Mulani PM, Gu Y, Okun MM. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study. Br J Dermatol 2012; 167: 658-67. http://dx.doi.org/10.1111/j.1365-2133.2012.11041.x
van den Reek JM, van Lümig PP, Kievit W, Zweegers J, van de Kerkhof PC, Seyger MM, de Jong EM. Effectiveness of adalimumab dose escalation, combination therapy of adalimumab with methotrexate, or both in patients with psoriasis in daily practice. J Dermatolog Treat 2013. http://dx.doi.org/10.3109/09546634.2012.751483
Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12? 23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial [PHOENIX 2
Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12? 23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial [PHOENIX 1
Vitiello M, Grant A, Kerdel FA. Ustekinumab: when everything else fails? Int J Dermatol 2011; 50: 478-82. http://dx.doi.org/10.1111/j.1365-4632.2010.04766.x
Buggiani G, D'Erme AM, Krysenka A, Pescitelli L, Lotti T, Prignano F. Efficacy of ustekinumab in sub-erythrodermic psoriasis: when TNF-blockers fail. Dermatol Ther 2012; 25: 283-85. http://dx.doi.org/10.1111/j.1529-8019.2012.01465.x
Viguier M, Livideanu C, Beylot-Barry M, Richard MA, Paul C, Bachelez H, Aubin F. for the Groupe de Recherche sur le Psoriasis. Observational case series on a group of psoriasis patients who failed to respond to any TNF blockers. J Dermatolog Treat 2013.
Ferrándiz C, García A, Blasco AJ, Lázaro P. Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol 2012; 26: 768-77. http://dx.doi.org/10.1111/j.1468-3083.2011.04357.x
Alandete JC. Effect of treatment switch on the cost-effectiveness biologics in psoriasis in Peru and Colombia. Value Health 2011; 14: A58.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2014 Joaquín Borrás-Blasco, Luisa Obon, Isabel Hernández, Dolores-Elvira Casterá, Alejandro Gonzalez, F. Javier Abad , J. Dolores Rosique-Robles